Acquisition history Coldstream Laboratories was acquired by Piramal Pharma Solutions in January 2015 for around $30M, indicating a history of strategic integration within a broader pharma services group and potential access to Piramal’s customer base, distribution channels, and capital resources for expansion.

Sterile and cytotoxic focus Specializes in aseptic and non-aseptic parenteral drug product manufacturing with mobile isolator technology for containment of potent and cytotoxic compounds, presenting opportunities to offer high containment CDMO services to biologics, oncology products, and radiolabeled therapies.

Mid-market scale Employee count and revenue positioning (11-50 employees, $50M–$100M revenue) signals a nimble, mid-market CDMO capable of faster decision cycles and customized collaborations, ideal for targeted partnerships with mid-size pharma and biotech companies.

Onsite capabilities In-house analytics, pre-formulation, formulation development, and microbiology testing offer end-to-end support, enabling bundled service proposals to reduce vendor management for clients needing integrated development-to-manufacturing workflows.

Strategic partnerships Existing brand associations and a broad tech stack paired with a history of acquisition suggest readiness for co-development or capacity expansion deals with larger CDMOs or pharma services groups seeking specialized sterile manufacturing capabilities.